Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 14 posts of 209 posts found.

Abasaglar

Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

News
lilly_corporate_hq

Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks

August 21, 2015
Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs

Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …

News
alzheimers_brain

Lilly, Biogen and Roche debut Alzheimer’s disease drug results

July 22, 2015
Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly

Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …

News
lilly_logo_building

Lilly and AstraZeneca collaborate on cancer trials

May 29, 2015
Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I

AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …

News

UK pharma commits at least ‘one code breach a week’

February 18, 2015
Medical Communications, Sales and Marketing ABPI, AstraZeneca, Bayer, Eli Lilly, GSK, Novartis, Novo Nordisk, PMCPA, Pfizer, code

Pharma companies commit unethical marketing practices on average more than once a week in the UK academic analysis has found. …

News
Cyramza

Lilly to market stomach cancer drug in Europe

December 22, 2014
Sales and Marketing Eli Lilly, Europe, FDA, US, cyramza, ramucirumab, stomach cancer

Eli Lilly has been granted permission by the European Commission to market Cyramza in Europe. Lilly’s Cyramza (ramucirumab) is the …

News
lilly_entrance_web

Lilly pessimistic on 2012 performance

January 6, 2012
Sales and Marketing Eli Lilly, lilly, zyprexa

Lilly is forecasting a drop in revenue and profits for 2012, as it prepares for life without its blockbuster antipsychotic …

News
richard_ashcroft

Eli Lilly appoints Richard Ascroft as senior director for the ACE region

November 30, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly

Lilly has appointed Richard Ascroft as senior director, corporate affairs, for the Australia, Canada and Europe (ACE) region. His tasks …

Appointment

Blood clot fears halt cancer trial enrolment

February 3, 2011
Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

News

Lilly Oncology chief resigns

January 27, 2011
Research and Development, Sales and Marketing Eli Lilly, John Johnson, Lilly Oncology, appointment, lilly, research and development, sales and marketing

Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced …

News

Lilly and Boehringer sign major diabetes collaboration

January 12, 2011
Research and Development BI10773, Boehringer Ingelheim, Eli Lilly, LY2605541, LY2963016, TGF-beta monoclonal antibody, diabetes, lilly, linagliptin, type II diabetes

Eli Lilly and Boehringer Ingelheim have signed a multi-million dollar collaboration that will see them develop and commercialise a mid- …

News

Patient deaths halt Lilly cancer trial

December 15, 2010
Research and Development Eli Lilly, lilly, melanoma, skin cancer, tasisulam

Lilly has been forced to halt phase III trials of its melanoma candidate tasisulam due to serious safety concerns over …

News

UK pharma faces rising costs from value-based pricing

December 3, 2010
Sales and Marketing Eli Lilly, VBP, lilly, value-based pricing

The government’s planned introduction of a value-based pricing system in the UK could increase costs and bureaucracy for the industry, …

News
Lilly headquarters

Lilly bolsters diagnostics presence with Avid acquisition

November 9, 2010
Research and Development Alzheimer's disease, Alzheimer’s disease, Avid Radiopharma, Eli Lilly, diabetes, emagacestat, florbetapir, lilly

Eli Lilly has acquired specialist diagnostics firm Avid Radiopharma in a deal that will bolster its diagnostics business. Philadelphia-based Avid …

News

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024